Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial

Mostrar otras versiones (1)

BACKGROUND: Giant-cell tumor of bone (GCTB) is a relatively benign, but locally aggressive osteoclastogenic stromal tumour of the bone. Although denosumab has been approved as an monoclonal antibody against RANK ligand for the treatment of GCTB, few clinical trials of the benefit in tumor response h...

Descripción completa

Detalles Bibliográficos
Autores principales: Yue, Jiaji, Sun, Wei, Li, Shenglong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254448/
https://www.ncbi.nlm.nih.gov/pubmed/35800292
http://dx.doi.org/10.1016/j.jbo.2022.100441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254448/
https://www.ncbi.nlm.nih.gov/pubmed/35800292
http://dx.doi.org/10.1016/j.jbo.2022.100441

Ejemplares similares